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Abstract Owing to their high efficacy, anthracycline
antibiotics are included in numerous chemotherapeutic
regimens used—often in combination with radiation ther-
apy and/or surgery—in treatment of solid tumours and
blood malignancies, both in children and adults. However,
the efficacy of modern cancer treatments, owing to which
the population of cancer survivors has been on the rise in
recent years, may be limited by the risk of serious com-
plications involving multiple organs and systems, including
the cardiovascular system. Being an important side effect
of anthracyclines, cardiotoxicity may limit the efficacy of
cancer therapies in the acute phase (i.e. during the treat-
ment) and induce the long-term sequelae, observed years
after treatment completion in childhood cancer survivors. It
is very important to understand the cardiotoxicity-associ-
ated mechanisms and to determine its risk factors in order
to develop and/or improve the effective countermeasures.
Based on published data, the paper provides an outline of
current views on anthracycline cardiotoxicity and discusses
such aspects as molecular mechanisms of cardiotoxicity
and its clinical manifestations as well as the new preventive
strategies and diagnostic techniques used for the assess-
ment of cardiovascular abnormalities. The widespread
awareness of cancer treatment-related cardiotoxicity
among the healthcare professionals may significantly im-
prove the quality of life of the childhood cancer survivors.
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Introduction
Modern cancer therapies have brought a major break-
through in paediatric oncology within the last 30 years.
Owing to this, we are able to cure approximately 70–80 %
children and adolescents with cancer, and in some types of
cancer the survival rates are as high as 100 % provided that
the diagnosis has been made early enough [4, 25]. The
efficacy of cancer treatment depends on the degree of
damage to the malignant cell population. That is why a
single chemotherapy regimen may include several agents
each of them having a different mechanism of action on
tumour cells. As a result, they show a cumulative adverse
effect on various organs and organ systems.
Being an important side effect of anthracyclines, car-
diotoxicity may limit the efficacy of cancer therapies in the
acute phase (i.e. during the treatment) and induce the long-
term sequelae, observed years after treatment completion
in childhood cancer survivors. Cardiovascular complica-
tions differ in type and severity depending on the actual
cancer treatment. Cancer survivors tend to develop heart
failure, ischaemic heart disease and cerebrovascular inci-
dents more often than the general population. The cardio-
vascular mortality rates among childhood cancer survivors
are Btenfold higher compared to the age-matched controls
[35, 44]. Chemotherapy, radiation therapy and new biolo-
gical therapies, used as a stand-alone treatment or in
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combination, constitute an important risk factor and pre-
dispose the patients to develop such complications.
Objective
Anthracycline Cardiotoxicity: Pathophysiology
Owing to their high efficacy, anthracycline antibiotics are
included in numerous chemotherapeutic regimens used in
treatment of solid tumours and blood malignancies, both in
children and adults. Anthracyclines exert their main
therapeutic effect by means of inserting (intercalation)
between the base pairs in the DNA double helix and in-
hibiting the enzymatic activity of topoisomerase-II, DNA
and RNA polymerases, helicases and DNA repair enzymes,
which ultimately inhibits tumour cell proliferation [17].
The toxic effect of anthracyclines on cardiovascular
system leads to the direct loss of cardiomyocytes, de-
creased cardiac muscle contractility and damage to the
microvasculature. Furthermore, by affecting cardiac pro-
genitor cells and fibroblasts, anthracyclines make it more
difficult for the already-weakened heart to recover from
injuries and the activity of other stressors, such as comor-
bidities or individual sensitivity [12].
Anthracycline cardiotoxicity involves multiple com-
plex mechanisms, which have not been fully understood
despite long-term research. The oxidative stress hy-
pothesis is one of the commonly accepted cellular
mechanisms to provide the potential explanation of car-
diotoxicity. According to this theory, reactive oxygen
species (ROS) and free radical formation directly trigger
cardiac damage in cancer survivors. Anthracyclines may
induce ROS formation via the enzymatic pathway, agly-
cone redox reaction and by forming iron complexes. The
free radicals target DNA molecules and proteins, but also
cellular membranes which contain large amounts of
phospholipids. Free radicals damage DNA and cause lipid
peroxidation, which in turn may lead to cell death and
large-scale organ damage. The dynamics of the oxidative
injury reflects and results from both oxidative stress and
the decreased antioxidant levels. Cardiac muscle is par-
ticularly susceptible to free radicals generated by anthra-
cycline antibiotics. Cardiomyocytes contain low levels of
free radical scavengers, such as catalase and glutation
peroxidase, which may cause their increased susceptibility
to the damage by ROS [5, 21].
However, newer studies show that the free radical theory
does not provide explanation to all aspects of anthracycline
toxicity. Although the precise molecular and cellular car-
diotoxicity mechanisms have not been fully explained, it is
commonly thought to originate from cardiomyocyte
apoptosis or necrosis and the sarcomere dysregulation and
dysfunction [12]. Anthracyclines potentially damage sev-
eral major structural proteins, which regulate cardiac
muscle contractility. One of them is titin, the myofilament
forming protein. Titin additionally regulates cardiac sys-
tolic function and sarcomere resting at diastole. Proteolysis
and titin decomposition may therefore lead to systolic and
diastolic dysfunction, typically present in patients treated
with anthracyclines [11, 12]. Another major structural
sarcomere protein, suggested as a potential target site of
anthracyclines, is dystrophin, whose damage may increase
the risk of dilated cardiomyopathy [10, 12].
However, there are also other mechanisms which con-
tribute to the toxic effect of anthracyclines on the cardiac
muscle. Anthracyclines may irreversibly disturb energy
production in cardiomyocytes, interfering with their ability
to induce the adequate contraction. They may also interfere
with ATP production in cardiomyocytes, reduce the ex-
pression of mitochondrial RNA (mRNA) for sarco/endo-
plasmic reticulum Ca2?-ATPase (SERCA), decrease the
activity of glutation peroxidase within the cardiac muscle
and induce breathing difficulties by damage to mitochon-
drial DNA [12, 50].
Eventually, understanding the role of signalling proteins
in cardiovascular system may help determine the actual
anthracycline cardiotoxicity mechanisms, which will
broaden our knowledge on the toxicity pathway itself and
contribute to its earlier detection. Owing to the synergistic
cardiotoxicity potential of anthracyclines and trastuzumab,
monoclonal antibody which disrupts the ErbB2 signalling
pathway, neuroregulin (NRG-1) has attracted increasing
attention. Neuroregulin is a growth factor, endogenous li-
gand of the ErbB2 protein. Having been activated by
binding to its ligand (i.e. neuroregulin-1) ErbB2 forms the
ErbB4 dimer, thus activating the tyrosine kinase signalling
pathway cascade, which promotes cardiomyocyte regen-
eration. After anthracycline administration, the level of
neuroregulin decreases, which may suggest the potential
toxicity mechanism [11, 17]. Recent studies show that
heart failure observed in adult breast cancer survivors
treated with anthracyclines and trastuzumab, can be at-
tributed to cardiomyocyte apoptosis and necrosis, triggered
by the direct anthracycline activity and trastuzumab-in-
duced inhibition of cardiomyocyte regeneration pathway
[11, 14]. The synergistic effect of trastuzumab and an-
thracyclines indicates the importance of crosstalk between
the significant cardiomyocyte regulation pathways and
sarcomere pathways, which are typically linked to the an-
thracycline toxicity. Furthermore, these results confirm the
hypothesis that the anthracycline-induced cardiomyocyte
damage combined with inhibition of physiological car-
diomyocyte regeneration pathway by other stressors in-
creases the risk of heart failure or other clinical
manifestations of cardiotoxicity [12].
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Clinical Manifestation of Anthracycline
Cardiotoxicity
The effect of anthracycline-based chemotherapy on human
heart may be manifested differently in different indi-
viduals. The most typical clinical manifestations of cardiac
muscle damage are as follows: asymptomatic ECG ab-
normalities, mild blood hypotension, cardiac arrhythmias,
electrical conduction dysfunction, myocarditis, pericarditis,
acute myocardial infarction, heart failure, and chronic di-
lated and/or restrictive cardiomyopathy [1, 5, 21, 33, 45].
That toxic effect of anthracyclines on cardiac muscle
can manifest at any stage of treatment. Based on the time of
onset, the following classification has been proposed:
• Acute or subacute cardiotoxicity—which develops
during anthracycline-based chemotherapy, after a sin-
gle administration or several cycles with a low
cumulative dose, or within a year from treatment
completion. This type of injury does not imply
cardiomyocyte loss, so it is typically transient, re-
versible and non-dose dependant. It affects less than
1 % of patients. This form of cardiotoxicity is
manifested clinically by paroxysmal arrhythmia, peri-
cardial exudate, left ventricular dysfunction and—
episodically—sudden cardiac death [21, 31].
• Early-onset chronic cardiotoxicity—which develops in
less than 1 year following completion of cancer treat-
ment and may be progressive. It affects approximately
2 % of patients [1, 5, 21, 31, 45].
• Chronic progressive late-onset cardiotoxicity—which
is dose dependant, develops within more than 1 year,
and often many years after cancer treatment comple-
tion. It is related to the irreversible cardiomyocyte loss.
In most cases, it remains asymptomatic for many years
as the subclinical anthracycline-induced cardiomyopa-
thy. It is the most commonly reported cardiac muscle
injury, which may affect—according to different
authors—5 up to 57 % of cancer patients [30]. How-
ever, with time, it may lead to the irreversible heart
injury which is symptomatized by the congestive heart
failure or myocardial infarction [1, 5, 21, 45].
The recent research shows that the asymptomatic diastolic
dysfunction, which is a common feature observed in many
cancer survivors, is the earliest noticeable cardiac abnor-
mality [20, 37]. By increasing calcium ion levels at diastole,
anthracyclines may increase the left ventricular wall stiff-
ness, simultaneously elevating the interstitial fluid pressure.
This decreases the coronary arterial compliance which may
lead to cardiac ischaemia. Subsequently, the abnormalities
of left ventricular geometry develop (ectasia) followed by
contractile dysfunction [36, 37]. Therefore, the left ven-
tricular diastolic dysfunction bridges a gap between cancer
treatment and cardiac ischaemia and/or systolic dysfunction.
Diastolic dysfunction and the resulting decreased coronary
arterial compliance make the heart more susceptible to co-
morbidities, which interfere with the coronary blood flow or
increase the oxygen demand, such as early atherosclerosis or
blood hypertension. The diastolic dysfunction may progress
to systolic failure in such mechanisms as inhibition of or
other stressors to human endothelial receptor-2 (HER-2),
which is crucial formyocyte survival and normalmyocardial
contractile function [37].
Risk Factors of Anthracycline Cardiotoxicity
Anthracycline toxicity and its clinical expression have
multiple modifiers. Some of them can be linked to cancer
treatment, whereas others are patient-related risk factors.
There have been many studies to assess the risk of early
and late anthracycline cardiotoxicity. Although their results
have not been fully uniform, they helped determine the
following risk factors for cardiovascular abnormalities in
cancer survivors.
• Total cumulative dose of anthracyclines—the therapeu-
tic efficacy of anthracyclines increases with the dose.
However, so does their cardiotoxicity. In clinical
studies on adults treated with doxorubicin, the risk for
heart failure was 3–5 % with the cumulative dose of
400 mg m2, went up to 7–26 % with the dose below
550 mg/m2 and further increased up to 48 % with the
dose of 700 mg/m2 [46]. Studies on childhood cancer
survivors showed that the risk of obvious heart failure
increases 11-fold in patient receiving doses over
300 mg/m2, as compared to ones treated with doses
below 300 mg/m2 [29]. Nevertheless, severe car-
diotoxicity symptoms were observed in patients receiv-
ing much lower doses of cytostatic agents, suggesting
an important role of individual susceptibility to
anthracyclines.
• Time from cancer diagnosis and the moment of
anthracycline treatment commencement—the long-
term studies in cancer survivors show that the risk of
cardiovascular complications increases with the length
of the follow-up [33].
• Very young or advanced age of patient at the moment of
diagnosis, i.e. age below 4 years is associated with the
increased risk of cardiotoxicity [33], although not all
researchers confirm this association [30, 41].
• Sex—the potential association of anthracycline car-
diotoxicity with female sex is emphasized. The actual
mechanism has not been fully understood. However,
sex-based differences in pharmacokinetics and phar-
macodynamics of cytostatic drugs appear to play the
role [33].
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• Black ethnicity [31].
• Down Syndrome [31].
• Chemotherapy combined with radiation therapy to the
mediastinum poses the highest risk of cardiac compli-
cations due to anatomical heart location [1, 21]. Early
radiation-induced injury primarily involves the peri-
cardium and manifests as acute pericarditis, which
usually develops in several weeks following treatment
completion. Coronary artery disease is the most com-
mon manifestation of late cardiovascular complications
of radiation therapy with a typical late onset, i.e. in
10–15 years following radiation therapy. It was shown
that ion radiation may induce or significantly accelerate
atherosclerosis, both in patients with insignificant
medical history and individuals with known cardiovas-
cular risk factors. If myocardial damage occurs,
restrictive cardiomyopathy will follow presenting as
diastolic dysfunction. Additionally, the systolic heart
function may become impaired and valvular heart
disease, cardiac arrhythmias or conductivity disorder
can develop [2, 6, 9].
• Chemotherapy combined with the administration of
other cardiotoxic agents increases toxic effect of
anthracyclines on cardiovascular system. The car-
diotoxic effect of cyclophosphamide, iphosphamide,
fluorouracil, bleomycin, vincristine, mitoxantrone and
trastuzumab [5, 21] has been proven.
• Cardiotoxicity may be induced or increased by the risk
factors for cardiovascular diseases and the comorbidi-
ties. They increase in number as the patient ages after
the treatment is completed. These factors include blood
hypertension, obesity and overweight, diabetes, dys-
lipidemia and imbalanced lifestyle with reduced
physical exercise and/or smoking, alcohol misuse,
stress and unhealthy diet. Similarly, other cardiovascu-
lar diseases, renal diseases, additional cardiovascular
strain due to pregnancy, surgery or increased body
weight can trigger cardiovascular symptoms in cancer
survivors after a long-term asymptomatic period [5, 17,
28, 36, 44].
Current Views on Cardiotoxicity
• The lifelong risk of cardiotoxicity
Understanding molecular assumptions of anthracycline-
associated cardiotoxicity as well as knowledge and the
detailed analysis of risk factors has changed the car-
diotoxicity profile of this drug family. As the anthracycline
doses were reduced, the incidence of acute cardiotoxicity
plummeted, but the incidence of late cardiovascular com-
plications did not, which may suggest that there is no an-
thracycline dose to be completely safe for human heart.
The presence of a long-term, lifelong anthracycline car-
diotoxicity risk has not been explained yet. It is known,
however, that anthracyclines are eliminated from the my-
ocardium quite fast and their level quickly drops below the
acute toxicity threshold [37, 42]. It was initially attributed
to mitochondrial dysfunction caused by exposure to dox-
orubicin, which led to the assumption that these abnor-
malities persist despite lack of continuous exposure to
doxorubicin [32, 37]. However, the preliminary results
from the animal models were not confirmed by studies on
humans. It is thought currently that doxorubicin and
daunomycin conversion to highly toxic C-13 alcohol
metabolites such as doxorubicinol and daunorubicinol of-
fers a better explanation of the lifelong risk of anthracy-
cline cardiotoxicity. The said anthracyclines are poorly
eliminated from cardiomyocytes and accumulate therein,
which is a long-term sequelae of their presence within the
cardiac muscle. Thus, it seems that alcohol metabolites of
anthracycline antibiotics, which are even more toxic than
their original compounds, may induce both early-onset
symptoms (i.e. occurring during the chemotherapy) and
late-onset symptoms (i.e. occurring many years after can-
cer treatment completion) [37]. Further research is required
in order to address this issue.
• Individual variability
The non-invasive tests showed that 50 % of patients
treated with anthracyclines in childhood (study group) had
some asymptomatic myocardial dysfunction, which
manifested as symptomatic incidents only in 5 % [39].
These data are similar in the group of adult cancer sur-
vivors, as well [23]. Individual and interracial variability
may explain why different patients receiving similar
treatment develop different symptoms of cardiotoxicity. It
is currently assumed that the presence of gene polymor-
phisms which modify the pharmacodynamic properties of
anthracyclines may result in variable cardiotoxicity effect
in different individuals [15, 49].
Recent studies confirm the role of functional polymor-
phisms of genes coding for carbonyl reductases (CBR1 and
CBR3), which regulate anthracycline conversion to their
alcohol metabolites, as the primary mechanism in the
etiopathogenesis of chronic anthracycline cardiomyopathy
in patients treated with daunorubicin. Homozygosity for
the major allele (G) in the CBR3 gene seems to increase
the risk of anthracycline-associated cardiomyopathy at the
exposure to low-to-moderate doses [7, 8]. The clinical
importance of these results is being verified.
• Multiple hit hypothesis
The risk of cardiotoxicity in cancer survivors increases
significantly at the presence of concomitant risk factors for
cardiovascular diseases, such as blood hypertension,
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hyperlipidaemia or imbalanced lifestyle [36]. The available
evidence also suggests that compared to age-matched
healthy individuals, cancer survivors—initially with in-
significant medical history—were diagnosed with the
higher number of comorbidities and their level of physical
activity dropped [13, 26]. This indicates that potentially
reversible asymptomatic cardiotoxicity associated with the
‘safe doses’ of anthracyclines or other chemotherapeutic
agents may progress to symptomatic incidents with over-
lapping risk factors which increase in number after the
treatment is completed [37]. This is the so-called multiple
hit hypothesis, which explains the late-onset cardiotoxicity
as being the cumulative result of multiple drug-induced and
non-drug-induced injuries to the cardiac muscle [26, 37].
That is why the direct effect of cytostatic drugs and im-
balanced lifestyle decrease the cardiovascular reserve, in-
creasing the risk of cardiovascular diseases and the
premature cardiovascular death.
Diagnosis and Monitoring of Cardiac Abnormalities
Standard management during anthracycline-based che-
motherapy involves cardiac function assessment prior to
treatment, monitoring potential cardiotoxicity during the
therapy as well as a long-term follow-up after the che-
motherapy is completed. In order to evaluate myocardial
abnormalities laboratory tests, genetic tests and cardio-
vascular diagnostic imaging have proved to be useful.
Such biochemistry markers of necrosis as T-troponin,
I-troponin and CKMB are useful in the acute phase of
myocardial injury. They are elevated very early, often
immediately after the first administration of anthracyclines.
That is why they do not make good diagnostic markers of
chronic cardiac injury. Similarly, more research on larger
patient samples is needed in order to confirm the applica-
bility of natriuretic peptide assays (NT-pro ANP and NT-
pro BNP) in detecting late anthracycline cardiotoxicity
[17]. Levels of these oligopeptide neurohormones correlate
with the left ventricular ejection fraction (LVEF) and
pulmonary capillary wedge pressure (PCWP). They do not
meet the screening test criteria; however, their concentra-
tion within the reference ranges excludes heart failure in
over 90 % of cases [40]. The search for new cardiotoxicity
markers has also been continued. The following substances
are proposed as potential markers: endothelin-1 (ET-1),
fatty-acid-binding protein (FABP), cytokines and intercel-
lular adhesion molecule-1 (ICAM-1) being the markers of
endothelial damage as well as tissue plasminogen activator
(TPA) and plasminogen activator inhibitor-1 (PAI-1) being
the components of plasma fibrinolytic system [3]. Another
approach proposes genetic testing aiming at early identifi-
cation of patients at high risk of cardiotoxicity.
Modification of cancer treatment in these patients may help
avoid severe cardiovascular complications.
The next stage of diagnosis involves diagnostic imaging
and LVEF assessment. Echocardiography is the most
commonly available and used cardiovascular diagnostic
imaging technique. It facilitates precise evaluation of heart
and large vessel morphology as well as diagnosis of sys-
tolic and diastolic dysfunction. Three-dimensional
echocardiography and quantitative assessment of intrinsic
regional myocardial deformation (strain and strain rate
technique) as well as tissue Doppler technique are the
imaging techniques hoped to improve the precision and
reproducibility of echocardiographic cardiac function pa-
rameters. The key role of echocardiography in the diag-
nosis of chemotherapy-induced cardiotoxic damage is
primarily due to the variability of assessed parameters, the
non-invasive nature of the procedure and the possibility to
repeat it as often as necessary [24, 27].
Radionuclide angiography (RNA) is an alternative
method for the diagnosis of cardiotoxic damage. Scintig-
raphy is also used for heart imaging in oncology, as it
enables the assessment of left ventricular function. This
includes such techniques as multiple-gated acquisition
scintigraphy (MUGA) with the use of technetium-99m
administered intravenously as a contrast agent, or indium-
111 antimyosin antibody scintigraphy. Metabolic dys-
function, fibrosis and necrosis can be evaluated using the
single-photon emission computed tomography (SPECT)
and positron emission tomography (PET). Cardiac muscle
biopsy is the most sensitive method to assess the car-
diotoxicity at the cellular level. It is an invasive procedure,
which limits its use to carefully selected cases. Similarly,
other diagnostic techniques mentioned above should also
be used after careful analysis of risk and cost against
benefits, in selected patients with known indications. They
are rarely used for screening or as a part of cancer treat-
ment monitoring. They are not commonly used due to
limited availability and high cost [16, 22, 38, 48].
Anthracycline Cardiotoxicity Prevention
The main purpose of all preventive strategies is to mini-
mize cardiotoxicity and to improve the efficacy of cancer
treatments. The currently used anthracycline car-
diotoxicity-preventive strategies include:
• Limited cumulative anthracycline dose—it is one of the
most commonly accepted heart damage prevention
methods. Therefore, the recommended highest doxoru-
bicin dose should fall within the range of 400–550 mg/
m2 and should not exceed 240 mg/m2 in most children
and adolescents [17, 43, 44]. However, it should be
emphasized that there is no completely safe dose of
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anthracyclines and even the lowest dose can induce
severe cardiotoxicity.
• Another subject for a discussion is the route of
administration, e.g. whether anthracyclines should be
administered as a short quick bolus or a slow infusion.
It is likely that heart injury does not depend on the
cumulative dose only but also on peak serum anthra-
cycline levels as well. Despite heterogeneous study
results, it should be assumed that anthracycline admin-
istration as a long-term (over 48 h), continuous infusion
can have the cardioprotective effect by means of
decreasing the maximum serum drug concentration.
Based on this assumption, many paediatric treatment
protocols recommend continuous infusion, although
long-term observation does not support its efficacy [17,
34].
• The use of anthracycline analogues and liposomal
anthracyclines: Anthracycline analogues such as epiru-
bicin, idarubicin or mitoxantrone are characterized by
the weaker toxic effect on the cardiac muscle. Clinical
studies showed lower cardiotoxicity of epirubicin,
which does not accumulate within the cardiac muscle
as doxorubicin does, whereas its efficacy is only
slightly decreased. Currently, the so-called liposomal
anthracyclines, also referred to as third-generation
anthracyclines, are frequently used. The use of modern
technology made it possible to transport the doxoru-
bicin on a liposomal carrier and to prolong the time it
remains within the circulation, just like the continuous
infusion. Liposomes are capable of transporting the
active substance selectively to the neoplastic tissue,
which limits the anthracycline contact with healthy
cells and tissues, thus limiting their toxicity to the
cardiac muscle [18, 19]. The use of pegylated doxoru-
bicin additionally decreases the risk of heart damage.
However, liposomal anthracycline forms are very
expensive, which limits their use.
• Cardioprotective agents—there have been attempts to
use the known drug interactions in order to decrease
anthracycline cardiotoxicity. The Q10 coenzyme, vi-
tamin E and carnitine, which are known for their
antioxidant properties, have been used. Another possi-
bility is to use dexrazoxane (Cardioxane) which exerts
its effect as iron chelator and inhibitor of free radical
formation in the heart. The preliminary results of
clinical trials of dexrazoxane on paediatric cancer
patients indicate its cardioprotective efficacy at the
early stages of treatment. The long-term effect, though,
still has to be confirmed. It has been reported that this
substance may reduce the efficacy of cancer therapies
[47]. Therefore, further research is necessary.
• It is particularly important to eliminate the classic
cardiovascular risk factors in cancer survivors.
Comorbidity prevention and lifestyle modification can
be used in these patients. Treatment can also be
commenced earlier and more aggressively compared to
the general population [17, 28, 34, 44].
Summary and Conclusion
To sum up, it should be emphasized that the effective
cancer treatment in children and adolescents is a huge
success of modern medicine. As a result, the population of
childhood cancer survivors is becoming more numerous
each year. Considering the anticipated progression-free
survival, the measures should be taken in order to limit the
late effect of cancer treatment on other organs and systems,
including cardiovascular system. That is why, having in
mind the quality of life of cancer survivors, it is so im-
portant to understand the key mechanisms of toxic effect of
anthracyclines on cardiovascular system, develop effective
prevention and treatment strategies as well as cardiovas-
cular monitoring system.
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